DepYmed to Present at the 9th World Rett Syndrome Congress FARMINGDALE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...

DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...

DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...

DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome FARMINGDALE, N.Y., May 03, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...